Royal Bank of Canada Lowers CG Oncology Price Target Amid Mixed Analyst Outlook

CG Oncology (NASDAQ: CGON) had its price target adjusted downward by analysts at Royal Bank Of Canada, from $81.00 to $79.00 in a recent report.

This adjustment comes after several other firms have increased their price targets for the biotech company. Piper Sandler and Truist Financial both raised their targets to $85.00, with Piper Sandler assigning an 'overweight' rating and Truist Financial retaining its 'buy' rating.

HC Wainwright, however, issued a more conservative estimate, maintaining its $100.00 target but lowering its FY2030 EPS forecast to $2.34 from $2.43.